<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Amatya E</submitter><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><pagination>e202400418</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11649481</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(24)</volume><pubmed_abstract>Heat Shock Protein 90 (Hsp90) is responsible for the proper folding and maturation of ~400 client protein substrates, many of which are directly associated with the ten hallmarks of cancer. Hsp90 is a great target for cancer therapy including melanoma, since Hsp90 inhibition can disrupt multiple oncogenic pathways simultaneously. In this study, we report the synthesis and anti-proliferative activity manifested by a series of Hsp90 C-terminal inhibitors against mutant BRAF and wild-type BRAF melanoma cells. Furthermore, we explored structure-activity relationships (SAR) for the amide moiety of 6 (B1), a novel Hsp90C-terminal inhibitor via introduction of amide bioisosteres. Compound 6 displayed an IC&lt;sub>50&lt;/sub> of 1.01 μM, 0.782 μM, 0.607 μM and 1.413 μM against SKMel173, SKMel103, SKMel1</pubmed_abstract><journal>ChemMedChem</journal><pubmed_title>The Investigation of Hsp90C-Terminal Inhibitors Containing Amide Bioisosteres.</pubmed_title><pmcid>PMC11649481</pmcid><funding_grant_id>R01 CA216919</funding_grant_id><funding_grant_id>CA270147</funding_grant_id><funding_grant_id>R01 CA270147</funding_grant_id><pubmed_authors>McNamara K</pubmed_authors><pubmed_authors>Amatya E</pubmed_authors><pubmed_authors>Cohen MS</pubmed_authors><pubmed_authors>Long R</pubmed_authors><pubmed_authors>Blagg BSJ</pubmed_authors><pubmed_authors>Subramanian C</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Investigation of Hsp90C-Terminal Inhibitors Containing Amide Bioisosteres.</name><description>Heat Shock Protein 90 (Hsp90) is responsible for the proper folding and maturation of ~400 client protein substrates, many of which are directly associated with the ten hallmarks of cancer. Hsp90 is a great target for cancer therapy including melanoma, since Hsp90 inhibition can disrupt multiple oncogenic pathways simultaneously. In this study, we report the synthesis and anti-proliferative activity manifested by a series of Hsp90 C-terminal inhibitors against mutant BRAF and wild-type BRAF melanoma cells. Furthermore, we explored structure-activity relationships (SAR) for the amide moiety of 6 (B1), a novel Hsp90C-terminal inhibitor via introduction of amide bioisosteres. Compound 6 displayed an IC&lt;sub>50&lt;/sub> of 1.01 μM, 0.782 μM, 0.607 μM and 1.413 μM against SKMel173, SKMel103, SKMel1</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2026-06-07T05:00:07.01Z</modification><creation>2026-06-07T03:06:29.81Z</creation></dates><accession>S-EPMC11649481</accession><cross_references><pubmed>39153203</pubmed><doi>10.1002/cmdc.202400418</doi></cross_references></HashMap>